Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
20 Mar 2024
Historique:
received: 11 11 2022
accepted: 20 02 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: aheadofprint

Résumé

Epstein-Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases

Identifiants

pubmed: 38509369
doi: 10.1038/s41586-024-07213-6
pii: 10.1038/s41586-024-07213-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Latour, S. & Fischer, A. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: lessons from genetic diseases. Immunol. Rev. 291, 174–189 (2019).
pubmed: 31402499 doi: 10.1111/imr.12791
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. & Hislop, A. D. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 33, 787–821 (2015).
pubmed: 25706097 doi: 10.1146/annurev-immunol-032414-112326
Dunmire, S. K., Hogquist, K. A. & Balfour, H. H. Infectious mononucleosis. Curr. Top. Microbiol. Immunol. 390, 211–240 (2015).
pubmed: 26424648 pmcid: 4670567
Tangye, S. G. & Latour, S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood 135, 644–655 (2020).
pubmed: 31942615 doi: 10.1182/blood.2019000928
Hirahara, K. et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity 42, 877–889 (2015).
pubmed: 25992861 doi: 10.1016/j.immuni.2015.04.014
Kastelein, R. A., Hunter, C. A. & Cua, D. J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221–242 (2007).
pubmed: 17291186 doi: 10.1146/annurev.immunol.22.012703.104758
Huang, Z. et al. IL-27 promotes the expansion of self-renewing CD8
pubmed: 31164392 pmcid: 6683984 doi: 10.1084/jem.20190173
Munz, C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat. Rev. Microbiol. 17, 691–700 (2019).
pubmed: 31477887 doi: 10.1038/s41579-019-0249-7
Shannon-Lowe, C. & Rickinson, A. The global landscape of EBV-associated tumors. Front. Oncol. 9, 713 (2019).
pubmed: 31448229 pmcid: 6691157 doi: 10.3389/fonc.2019.00713
Callan, M. F. et al. Direct visualization of antigen-specific CD8
pubmed: 9565632 pmcid: 2212279 doi: 10.1084/jem.187.9.1395
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7
Sprecher, C. A. et al. Cloning and characterization of a novel class I cytokine receptor. Biochem. Biophys. Res. Commun. 246, 82–90 (1998).
pubmed: 9600072 doi: 10.1006/bbrc.1998.8576
Pflanz, S. et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172, 2225–2231 (2004).
pubmed: 14764690 doi: 10.4049/jimmunol.172.4.2225
Chen, Q. et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407, 916–920 (2000).
pubmed: 11057672 doi: 10.1038/35038103
Owaki, T. et al. A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. 175, 2191–2200 (2005).
pubmed: 16081786 doi: 10.4049/jimmunol.175.4.2191
Yoshida, H. & Hunter, C. A. The immunobiology of interleukin-27. Annu. Rev. Immunol. 33, 417–443 (2015).
pubmed: 25861977 doi: 10.1146/annurev-immunol-032414-112134
Artis, D. et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173, 5626–5634 (2004).
pubmed: 15494513 doi: 10.4049/jimmunol.173.9.5626
Schneider, R., Yaneva, T., Beauseigle, D., El-Khoury, L. & Arbour, N. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur. J. Immunol. 41, 47–59 (2011).
pubmed: 21182076 doi: 10.1002/eji.201040804
Charlot-Rabiega, P., Bardel, E., Dietrich, C., Kastelein, R. & Devergne, O. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4
pubmed: 21669870 pmcid: 3149329 doi: 10.1074/jbc.M111.221010
Pflanz, S. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4
pubmed: 12121660 doi: 10.1016/S1074-7613(02)00324-2
Pagano, G. et al. Interleukin-27 potentiates CD8
Harker, J. A. et al. Interleukin-27R signaling mediates early viral containment and impacts innate and adaptive immunity after chronic lymphocytic choriomeningitis virus infection. J. Virol. https://doi.org/10.1128/JVI.02196-17 (2018).
Pratumchai, I. et al. B cell-derived IL-27 promotes control of persistent LCMV infection. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2116741119 (2022).
Devergne, O., Birkenbach, M. & Kieff, E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl Acad. Sci. USA 94, 12041–12046 (1997).
pubmed: 9342359 pmcid: 23696 doi: 10.1073/pnas.94.22.12041
Devergne, O. et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol. 70, 1143–1153 (1996).
pubmed: 8551575 pmcid: 189923 doi: 10.1128/jvi.70.2.1143-1153.1996
Niedobitek, G., Pazolt, D., Teichmann, M. & Devergne, O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J. Pathol. 198, 310–316 (2002).
pubmed: 12375263 doi: 10.1002/path.1217
Larousserie, F. et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am. J. Pathol. 166, 1217–1228 (2005).
pubmed: 15793300 pmcid: 1602381 doi: 10.1016/S0002-9440(10)62340-1
Kang, M. S. & Kieff, E. Epstein-Barr virus latent genes. Exp. Mol. Med. 47, e131 (2015).
pubmed: 25613728 pmcid: 4314583 doi: 10.1038/emm.2014.84
Tosato, G. et al. Monocyte-derived human B-cell growth factor identified as interferon-β
pubmed: 2829354
Tosato, G., Tanner, J., Jones, K. D., Revel, M. & Pike, S. E. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J. Virol. 64, 3033–3041 (1990).
pubmed: 2159561 pmcid: 249488 doi: 10.1128/jvi.64.6.3033-3041.1990
Chehboun, S. et al. Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling. J. Biol. Chem. 292, 6644–6656 (2017).
pubmed: 28280243 pmcid: 5399113 doi: 10.1074/jbc.M116.762021
Puel, A., Bastard, P., Bustamante, J. & Casanova, J. L. Human autoantibodies underlying infectious diseases. J. Exp. Med. https://doi.org/10.1084/jem.20211387 (2022).
Kisand, K. et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299–308 (2010).
pubmed: 20123959 pmcid: 2822605 doi: 10.1084/jem.20091669
Puel, A. et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291–297 (2010).
pubmed: 20123958 pmcid: 2822614 doi: 10.1084/jem.20091983
Nanki, T. et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann. Rheum. Dis. 72, 1100–1102 (2013).
pubmed: 23349134 doi: 10.1136/annrheumdis-2012-202768
Puel, A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647–654 (2008).
pubmed: 18097067 doi: 10.4049/jimmunol.180.1.647
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science https://doi.org/10.1126/science.abd4585 (2020).
Bastard, P. et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. https://doi.org/10.1084/jem.20202486 (2021).
Zhang, Q. et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. https://doi.org/10.1084/jem.20220514 (2022).
Fournier, B. & Latour, S. Immunity to EBV as revealed by immunedeficiencies. Curr. Opin. Immunol. 72, 107–115 (2021).
pubmed: 33989894 doi: 10.1016/j.coi.2021.04.003
Kawamoto, K. et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica 103, 1018–1028 (2018).
pubmed: 29242302 pmcid: 6058795 doi: 10.3324/haematol.2017.174177
Alosaimi, M. F. et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J. Allergy Clin. Immunol. 144, 574–583 (2019).
pubmed: 30872117 pmcid: 6688916 doi: 10.1016/j.jaci.2019.03.002
Rodriguez, R. et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J. Exp. Med. 216, 2800–2818 (2019).
pubmed: 31537641 pmcid: 6888974 doi: 10.1084/jem.20190678
Somekh, I. et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood 134, 1510–1516 (2019).
pubmed: 31501153 pmcid: 6839947 doi: 10.1182/blood.2019000644
Hoshino, Y., Nishikawa, K., Ito, Y., Kuzushima, K. & Kimura, H. Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis. J. Clin. Virol. 50, 244–246 (2011).
pubmed: 21185773 doi: 10.1016/j.jcv.2010.11.017
Martin, E. et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature 510, 288–292 (2014).
pubmed: 24870241 pmcid: 6485470 doi: 10.1038/nature13386
Yamazaki, Y. et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J. Immunol. 193, 4880–4887 (2014).
pubmed: 25288569 doi: 10.4049/jimmunol.1401467
Toubiana, J. et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127, 3154–3164 (2016).
pubmed: 27114460 pmcid: 4920021 doi: 10.1182/blood-2015-11-679902
Izawa, K. et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J. Exp. Med. 214, 73–89 (2017).
pubmed: 28011863 pmcid: 5206497 doi: 10.1084/jem.20160784
Durandy, A., Kracker, S. & Fischer, A. Primary antibody deficiencies. Nat. Rev. Immunol. 13, 519–533 (2013).
pubmed: 23765059 doi: 10.1038/nri3466
Fournier, B. et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J. Exp. Med. https://doi.org/10.1084/jem.20192262 (2020).
McStay, G. P., Salvesen, G. S. & Green, D. R. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 15, 322–331 (2008).
pubmed: 17975551 doi: 10.1038/sj.cdd.4402260
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700 doi: 10.1093/bioinformatics/btu638
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210 (2002).
pubmed: 11752295 pmcid: 99122 doi: 10.1093/nar/30.1.207

Auteurs

Emmanuel Martin (E)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Sarah Winter (S)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Université Paris Cité, Paris, France.

Cécile Garcin (C)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Université Paris Cité, Paris, France.

Kay Tanita (K)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Akihiro Hoshino (A)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Christelle Lenoir (C)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Benjamin Fournier (B)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Mélanie Migaud (M)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.

David Boutboul (D)

Université Paris Cité, Paris, France.
Department of Hematology, Cochin Hospital, AP-HP, Paris, France.

Mathieu Simonin (M)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Alicia Fernandes (A)

Plateforme Vecteurs Viraux et Transfert de Gènes, Institut Necker Enfants Malades, Necker-Enfants Malades Hospital, APHP, Paris, France.

Paul Bastard (P)

Université Paris Cité, Paris, France.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.

Tom Le Voyer (T)

Université Paris Cité, Paris, France.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.

Anne-Laure Roupie (AL)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Université Paris Cité, Paris, France.

Yassine Ben Ahmed (Y)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.

Marianne Leruez-Ville (M)

Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France.

Marianne Burgard (M)

Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France.

Geetha Rao (G)

Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.

Cindy S Ma (CS)

Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia.

Cécile Masson (C)

Plateforme de Bioinformatique, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France.

Claire Soudais (C)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Université Paris Cité, Paris, France.

Capucine Picard (C)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Université Paris Cité, Paris, France.
Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France.

Jacinta Bustamante (J)

Université Paris Cité, Paris, France.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.
Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France.
St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

Stuart G Tangye (SG)

Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia.

Nathalie Cheikh (N)

Hôpital Jean Minjoz, Centre Hospitalo-Universitaire de Besançon, Besançon, France.

Mikko Seppänen (M)

Pediatric Research Center and Rare Disease Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.

Anne Puel (A)

Université Paris Cité, Paris, France.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.
St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.

Mark Daly (M)

Institut for Molecular Medecine Finland, University of Helsinki, Helsinki, Finland.

Jean-Laurent Casanova (JL)

Université Paris Cité, Paris, France.
Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France.
St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Howard Hughes Medical Institute, New York, NY, USA.

Bénédicte Neven (B)

Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Alain Fischer (A)

Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Collège de France, Paris, France.
Imagine Institute, INSERM UMR 1163, Paris, France.

Sylvain Latour (S)

Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France. sylvain.latour@inserm.fr.
Université Paris Cité, Paris, France. sylvain.latour@inserm.fr.

Classifications MeSH